• 1  Irgens LM, Bjerkedal T. Epidemiology of leprosy in Norway. The history of the National Leprosy Registry of Norway from 1856 until today. Int J Epidemiol 1973;2:819. Cross Ref link Pubmed link
  • 2  Hansen GA. [Undersolgelser angraaende spedalskhedens aasger.] Norsk Magazin Laegervidens Kaben 1874;4 (Suppl.):188.
  • 3  Anonymous. Leprosy: global situation 2012. Wkly Epidemiol Rec 2012;87:31728. Pubmed link
  • 4  Lockwood DN, Reid AJ. The diagnosis of leprosy is delayed in the United Kingdom. QJM 2001;94:20712. Cross Ref link Pubmed link
  • 5  Noordeen SK. Mortality in leprosy. Indian J Med Res 1972;60:43945. Pubmed link
  • 6  Noordeen SK. The epidemiology of leprosy. In: Hastings RC, ed. Leprosy. Edinburgh: Churchill Livingstone, 1994:1530.
  • 7  Fine PE. Leprosy: the epidemiology of a slow bacterium. Epidemiol Rev 1982;4:16188. Pubmed link
  • 8  Feldman RA, Sturdivant M. Leprosy in Louisiana, 1855–1970. An epidemiologic study of long‐term trends. Am J Epidemiol 1975;102:30310. Pubmed link
  • 9  Mira MT, Alcaïs A, Thuc NV, et al. Susceptibility to leprosy is associated with PARK2 and PACRG. Nature 2004;427:63640. Cross Ref link Pubmed link
  • 10  Ciechanover A. The ubiquitin proteolytic system. Neurology 2006;66(Suppl. 1):113. Cross Ref link Pubmed link
  • 11  Roy S, Frodsham A, Saha B, et al. Association of vitamin D receptor genotype with leprosy type. J Infect Dis 1999;179:18791. Cross Ref link Pubmed link
  • 12  Roy S, McGuire W, Mascie‐Taylor CG, et al. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy. J Infect Dis 1997;176:5302. Cross Ref link Pubmed link
  • 13  Santos AR, Suffys PN, Vanderborght PR, et al. Role of tumor necrosis factor‐alpha and interleukin‐10 promoter gene polymorphisms in leprosy. J Infect Dis 2002;186:168791. Cross Ref link Pubmed link
  • 14  Fitness J, Floyd S, Warndorff DK, et al. Large‐scale candidate gene study of leprosy susceptibility in the Karonga district of northern Malawi. Am J Trop Med Hyg 2004;71:33040. Pubmed link
  • 15  Moraes MO, Pacheco AG, Schonkeren JJ, et al. Interleukin‐10 promoter single‐nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes Immun 2004;5:5925. Cross Ref link Pubmed link
  • 16  Malhotra D, Darvishi K, Sood S, et al. IL‐10 promoter single nucleotide polymorphisms are significantly associated with resistance to leprosy. Hum Genet 2005;118:295300. Cross Ref link Pubmed link
  • 17  Sampaio EP, Caneshi JR, Nery JA, et al. Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus‐infected individuals. Infect Immun 1995;63:184854. Pubmed link
  • 18  Lawn SD, Wood C, Lockwood DNJ. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immuno‐deficiency virus‐infected person. Clin Infect Dis 2003;36:e56. Cross Ref link Pubmed link
  • 19  Ustianowski AP, Lawn SD, Lockwood DNJ. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis 2006;6:35060. Cross Ref link Pubmed link
  • 20  Deps P, Lucas S, Porro AM. Clinical and histological features of leprosy and HIV co‐infection in Brazil. Br J Dermatol 2013;38:4707.
  • 21  Rees RJ, Meade TW. Comparison of the modes of spread and the incidence of tuberculosis and leprosy. Lancet 1974;1:478. Cross Ref link Pubmed link
  • 22  Gill AL, Bell DR, Gill GV, et al. Leprosy in Britain: 50 years experience in Liverpool. QJM 2005;98:50511. Cross Ref link Pubmed link
  • 23  Beyene D, Aseffa A, Harboe M, et al. Nasal carriage of Mycobacterium leprae DNA in healthy individuals in Lega Robi village, Ethiopia. Epidemiol Infect 2003;131:8418. Cross Ref link Pubmed link
  • 24  Chehl S, Job CK, Hastings RC. Transmission of leprosy in nude mice. Am J Trop Med Hyg 1985;34:11616. Pubmed link
  • 25  Ridley DS. Pathogenesis of Leprosy and Related Diseases. London: Wright, 1988.
  • 26  Myrvang B, Godal T, Feek CM, et al. Immune response to Mycobacterium leprae in indeterminate leprosy patients. Acta Pathol Microbiol Scand [B] Microbiol Immunol 1973;81:61520. Pubmed link
  • 27  Drutz DJ, Chen TS, Lu WH. The continuous bacteremia of lepromatous leprosy. N Engl J Med 1972;287:15964. Cross Ref link Pubmed link
  • 28  Jopling WH. Reactions in leprosy. Lepr Rev 1970;41:623. Pubmed link
  • 29  Dastur DK. Cutaneous nerves in leprosy: the relationship between histopathology and cutaneous sensibility. Brain 1955;78:61533. Cross Ref link Pubmed link
  • 30  Shah PK, Malhotra YK, Lakhotia M, et al. Cardiovascular dysautonomia in patients with lepromatous leprosy. Indian J Lepr 1990;62:917. Pubmed link
  • 31  Beck JS, Abbot NC, Samson PD, et al. Impairment of vasomotor reflexes in the fingertips of leprosy patients. J Neurol Neurosurg Psychiatry 1991;54:96571. Cross Ref link Pubmed link
  • 32  Antia NH, Mehta L, Shetty V, Irani PF. Clinical, electrophysiological, quantitative, histologic and ultrastructural studies of the index branch of the radial cutaneous nerve in leprosy. I. Preliminary report. Int J Lepr Other Mycobact Dis 1975;43:10613. Pubmed link
  • 33  Mehta LN, Shetty VP, Antia NH, Irani PF. Quantitative, histologic and ultrastructural studies of the index branch of the radial cutaneous nerve in leprosy and its correlation with electrophysiologic study. Int J Lepr Other Mycobact Dis 1975;43:25664. Pubmed link
  • 34  Shetty VP, Mehta LN, Irani PF, Antia NH. Study of the evolution of nerve damage in leprosy. Part I – lesions of the index branch of the radial cutaneous nerve in early leprosy. Lepr India 1980;52:518. Pubmed link
  • 35  Weddell GM, Pearson JM. Leprosy – histopathologic aspects of nerve involvement. Contemp Neurol Ser 1975;12:1728. Pubmed link
  • 36  Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five‐group system. Int J Lepr Other Mycobact Dis 1966;34:25573. Pubmed link
  • 37  Job CK, Desikan KV. Pathologic changes and their distribution in peripheral nerves in lepromatous leprosy. Int J Lepr Other Mycobact Dis 1968;36:25770. Pubmed link
  • 38  Job CK. Pathology of peripheral nerve lesions in lepromatous leprosy – a light and electron microscopic study. Int J Lepr Other Mycobact Dis 1971;39:25168. Pubmed link
  • 39  Job CK. Mechanism of nerve destruction in tuberculoid‐borderline leprosy. An electron‐microscopic study. J Neurol Sci 1973;20:2538. Cross Ref link Pubmed link
  • 40  Ridley DS, Radia KB. The histological course of reactions in borderline leprosy and their outcome. Int J Lepr Other Mycobact Dis 1981;49:38392. Pubmed link
  • 41  Lockwood DN, Lucas SB, Desikan KV, et al. The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol 2008;61:595600. Cross Ref link Pubmed link
  • 42  Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004;363:120919. Cross Ref link Pubmed link
  • 43  Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through Toll‐like receptors. Science 1999;285:7323. Cross Ref link Pubmed link
  • 44  Krutzik SR, Ochoa MT, Sieling PA, et al. Activation and regulation of Toll‐like receptors 2 and 1 in human leprosy. Nature Med 2003;9:52532. Cross Ref link Pubmed link
  • 45  Demangel C, Britton WJ. Interaction of dendritic cells with mycobacteria: where the action starts. Immunol Cell Biol 2000;78:31824. Cross Ref link Pubmed link
  • 46  Birdi TJ, Antia NH. The macrophage in leprosy: a review on the current status. Int J Lepr Other Mycobact Dis 1989;57:51125. Pubmed link
  • 47  Lee SP, Stoker NG, Grant KA, et al. Cellular immune responses of leprosy contacts to fractionated Mycobacterium leprae antigens. Infect Immun 1989;57:247580. Pubmed link
  • 48  Modlin RL, Hofman FM, Horwitz DA, et al. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. J Immunol 1984;132:308590. Pubmed link
  • 49  Ilangumaran S, Shankernarayan N, Ramu G, Muthukkaruppan V. Antibody response to recombinant 65‐kDa, 70‐kDa and 18‐kDa mycobacterial antigens in leprosy patients and healthy contacts in a leprosy‐endemic population. Int J Lepr Other Mycobact Dis 1984;62:24555.
  • 50  Paul RC, Stanford JL, Carswell JW. Multiple skin testing in leprosy. J Hyg (Lond) 1975;75:5768. Cross Ref link Pubmed link
  • 51  Modlin RL, Melancon‐Kaplan J, Young SM, et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci USA 1988;85:121317. Cross Ref link Pubmed link
  • 52  Haregewoin A, Godal T, Mustafa AS, et al. T‐cell conditioned media reverse T‐cell unresponsiveness in lepromatous leprosy. Nature 1983;303:3424. Cross Ref link Pubmed link
  • 53  Kaplan G, Kiessling R, Teklemariam S, et al. The reconstitution of cell‐mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med 1989;169:893907. Cross Ref link Pubmed link
  • 54  Khanolkar‐Young S, Rayment N, Brickell PM, et al. Tumour necrosis factor‐α (TNF‐α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 1995;99:196202. Cross Ref link Pubmed link
  • 55  Yamamura M, Wang X‐H, Ohmen JD, et al. Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992;149:14705. Pubmed link
  • 56  Wemambu SN, Turk JL, Waters MF, Rees RJ. Erythema nodosum leprosum: a clinical manifestation of the arthus phenomenon. Lancet 1969;2:9335. Cross Ref link Pubmed link
  • 57  Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008;102:32937. Cross Ref link Pubmed link
  • 58  Dharma Rao T, Ramchander Rao P. Enhanced cell‐mediated immune response in erythema nodosum leprosum reactions of leprosy. Int J Lepr Other Mycobact Dis 1987;55:3642. Pubmed link
  • 59  Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor‐α and interleukin‐1β during leprosy reactional states. Clin Exp Immunol 1991;84:1038. Pubmed link
  • 60  Levy L, Ji B. The mouse foot‐pad technique for cultivation of Mycobacterium leprae. Lepr Rev 2006;77:524. Pubmed link
  • 61  Rees RJW. Animal models in leprosy. In: Rees RJW, ed. Tuberculosis and Leprosy. British Medical Bulletin, Vol. 44. Edinburgh: Churchill Livingstone, 1988:65064.
  • 62  Storrs EE. The nine‐banded armadillo: a model for leprosy and other biomedical research. Int J Lepr Other Mycobact Dis 1971;39:70314. Pubmed link
  • 63  Truman R, Singh P, Sharma S. Probable zoonotic for leprosy in the Southern United States. N Engl J Med 2011;364:162633 Cross Ref link Pubmed link
  • 64  Cole ST, Eiglmeier K, Parkhill J, et al. Massive gene decay in the leprosy bacillus. Nature 2001;409:100711. Cross Ref link Pubmed link
  • 65  Eiglmeier K, Cole ST. The integrated genome map of Mycobacterium leprae. Lepr Rev 2001;72:4629. Pubmed link
  • 66  Monot M, Honore N, Garnier N, et al. On the origin of leprosy. Science 2005;308(5724):10402. Cross Ref link Pubmed link
  • 67  Schuenemann VJ, Singh P, Mendum T. A genome‐wide comparison of medieval and modern Mycobacterium leprae. Science 2013;341:17983. Cross Ref link Pubmed link
  • 68  Han XY, Silva O. On the age of leprosy. PLOS Negl Trop Dis 2014;Feb 8(2):e2544. Cross Ref link Pubmed link
  • 69  Rivoire B, Pessolani MC, Bozic CM, et al. Chemical definition, cloning, and expression of the major protein of the leprosy bacillus. Infect Immun 1994;62:241725. Pubmed link
  • 70  Jamil S, Keer JT, Lucas SB, et al. Use of polymerase chain reaction to assess efficacy of leprosy chemotherapy. Lancet 1993;342:2648. Cross Ref link Pubmed link
  • 71  Honore N, Cole ST. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 1993;37:41418. Cross Ref link Pubmed link
  • 72  Brubaker ML, Binford CH, Trautman JR. Occurrence of leprosy in US veterans after service in endemic areas abroad. Public Health Rep 1969;84:10518. Cross Ref link Pubmed link
  • 73  Bryceson AD, Pfalzgraff RE. Leprosy, 3rd edn. Edinburgh: Churchill Livingstone, 1990.
  • 74  Sehgal VN, Srivastava G. Indeterminate leprosy. A passing phase in the evolution of leprosy. Lepr Rev 1987;58:2919. Pubmed link
  • 75  Iveson JM, McDougall AC, Leathem AJ, Harris HJ. Lepromatous leprosy presenting with polyarthritis, myositis, and immune‐complex glomerulonephritis. BMJ 1975;3:61921. Cross Ref link Pubmed link
  • 76  Malin AS, Waters MF, Shehade SA, Roberts MM. Leprosy in reaction: a medical emergency. BMJ 1991;302:13246. Cross Ref link Pubmed link
  • 77  Barton RP. A clinical study of the nose in lepromatous leprosy. Lepr Rev 1974;45:13544. Pubmed link
  • 78  Moller‐Christensen V. Changes in the anterior nasal spine and the alveolar process of the macillae in leprosy: a clinical examination. Int J Lepr Other Mycobact Dis 1974;42:4315. Pubmed link
  • 79  Latapi L, Chevez Zamora A. The ‘spotted’ leprosy of Lucio (la lepra ‘manchada’ de Lucio). An introduction to its clinical and histological study. Int J Lepr Other Mycobact Dis 1948;16:4219.
  • 80  Wade HW. The histoid variety of lepromatous leprosy. Int J Lepr Other Mycobact Dis 1963;31:12942.
  • 81  Suneetha S, Arunthathi S, Chandi S, Kurian N, Chacko CJ. Histological studies in primary neuritic leprosy: changes in the apparently normal skin. Lepr Rev 1998;69:3517. Pubmed link
  • 82  Mahajan PM, Jogaikar DG, Mehta JM. A study of pure neuritic leprosy: clinical experience. Indian J Lepr 1996;68:13741. Pubmed link
  • 83  Matthews LVB. Sarcoidosis of the nervous system. J Neurol Neurosurg Psychiatry 1965;28:23. Cross Ref link Pubmed link
  • 84  Bryceson AD. Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease. Trans R Soc Trop Med Hyg 1969;63:70837. Cross Ref link Pubmed link
  • 85  Munro DD, Du Vivier A, Jopling WH. Post kala‐azar dermal leishmaniasis. Br J Dermatol 1972;87:3748. Cross Ref link Pubmed link
  • 86  Nunzi E, Fiallo P. Differential diagnosis. In: Hastings RC, ed. Leprosy. Edinburgh: Churchill Livingstone, 1994:291313.
  • 87  Lockwood DN, Vinayakumar S, Stanley JN, et al. Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India. Int J Lepr Other Mycobact Dis 1993;61:815. Pubmed link
  • 88  Van Brakel WH, Nicholls PG, Das L, et al. The INFIR Cohort Study: assessment of sensory and motor neuropathy in leprosy at baseline. Lepr Rev 2005;76:27795. Pubmed link
  • 89  Pocaterra L, Jain S, Reddy R, et al. Clinical course of erythema nodosum leprosum: an 11‐year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006;74:86879. Pubmed link
  • 90  Kahawita IP, Lockwood DN. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008;102:32937. Cross Ref link Pubmed link
  • 91  Walker SL, Waters M, Lockwood DNJ. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007;78:197215. Pubmed link
  • 92  Rea TH, Ridley DS. Lucio's phenomenon: a comparative histological study. Int J Lepr Other Mycobact Dis 1979;47:1616. Pubmed link
  • 93  Pearson JM, Ross WF. Nerve involvement in leprosy – pathology, differential diagnosis and principles of management. Lepr Rev 1975;46:199212. Pubmed link
  • 94  Dabholkar VR, Gaitonde BB. A study of autonomic functions in leprosy. Lepr India 1982;54:30317. Pubmed link
  • 95  Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy. Design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (the Bangladesh Acute Nerve Damage Study). Lepr Rev 1999;70:14059. Pubmed link
  • 96  Saunderson P, Gebre S, Desta K, et al. The pattern of leprosy‐related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev 2000;71:285308. Pubmed link
  • 97  Courtright P, Daniel E, Sundarrao Ravenes J, et al. Eye disease in multibacillary leprosy patients at the time of their leprosy diagnosis: findings from the Longitudinal Study of Ocular Leprosy (LOSOL) in India, the Philippines and Ethiopia. Lepr Rev 2002;73:22538. Pubmed link
  • 98  Hogeweg M, Faber WR. Progression of eye lesions in leprosy. Ten‐year follow‐up study in the Netherlands. Int J Lepr Other Mycobact Dis 1991;59:3927. Pubmed link
  • 99  Guinto RS, Abalos RM, Cellona RV. An Atlas of Leprosy. Tokyo: Sasakawa Memorial Health Foundation, 1983.
  • 100  Ridley DS. Therapeutic trials in leprosy using serial biopsies. Lepr Rev 1958;29:4552. Pubmed link
  • 101  World Health Organization. Guidelines for slit skin smears. Int J Lepr Other Mycobact Dis 1987;55:4212.
  • 102  Ridley DS. Skin Biopsy in Leprosy. Basel: Documenta Geigy, 1977.
  • 103  Smith PG. The serodiagnosis of leprosy. Lepr Rev 1992;63:97100. Pubmed link
  • 104  Bührer‐Sékula S, Visschedijk J, Grossi MA, et al. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients. Lepr Rev 2007;78:709. Pubmed link
  • 105  Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999;67:612. Pubmed link
  • 106  Ji BH. Drug resistance in leprosy – a review. Lepr Rev 1985;56:26578. Pubmed link
  • 107  World Health Organization. Chemotherapy of Leprosy for Control Programmes. Technical Report Series 675. Geneva: World Health Organization, 1982.
  • 108  Levy L, Shepard CC, Fasal P. The bactericidal effect of rifampicin on M. leprae in man: (a) single doses of 600, 900 and 1200 mg; and (b) daily doses of 300 mg. Int J Lepr Other Mycobact Dis 1976;44:1837. Pubmed link
  • 109  Jacobson RR, Hastings RC. Rifampin‐resistant leprosy. Lancet 1976;2:13045. Cross Ref link Pubmed link
  • 110  Frey HM, Gershon AA, Borkowsky W, Bullock WE. Fatal reaction to dapsone during treatment of leprosy. Ann Intern Med 1981;94:7779. Cross Ref link Pubmed link
  • 111  World Health Organization. Chemotherapy of Leprosy. Technical Report Series 847. Geneva: World Health Organization, 1994.
  • 112  Lockwood DN. Leprosy. Clin Evid 2002;8:70920. Pubmed link
  • 113  Gebre S, Saunderson P, Byass P. Relapses after fixed duration multiple drug therapy: the AMFES cohort. Lepr Rev 2000;71:32531. Pubmed link
  • 114  Boerrigter G, Ponnighaus JM, Fine PE, Wilson RJ. Four‐year follow‐up results of a WHO‐recommended multiple‐drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr Other Mycobact Dis 1991;59:25561. Pubmed link
  • 115  Dasananjali K, Schreuder PA, Pirayavaraporn C. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand: a prospective study, 1984–96. Int J Lepr Other Mycobact Dis 1997;65:2836. Pubmed link
  • 116  Jamet P, Ji B. Relapse after long‐term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 1995;63:195201. Pubmed link
  • 117  Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 2000;71:14453. Pubmed link
  • 118  Ji B. Rifampicin resistant leprosy: a review and a research proposal of a pilot study. Lepr Rev 2002;73:28. Pubmed link
  • 119  World Health Organization. Report of the Third Meeting of the WHO Technical Advisory Group on the Elimination of Leprosy. Geneva: WHO/CDS/CPE/CEE, 2002.
  • 120  Lockwood DN. Leprosy elimination – a virtual phenomenon or a reality? BMJ 2002;324:151618. Cross Ref link Pubmed link
  • 121  N'Deli L, Guelpa‐Lauras CC, Perani EG, Grosset JH. Effectiveness of pefloxacin in the treatment of lepromatous leprosy. Int J Lepr Other Mycobact Dis 1990;58:1218. Pubmed link
  • 122  Gelber RH, Fukuda K, Byrd S, et al. A clinical trial of minocycline in lepromatous leprosy. BMJ 1992;304:912. Cross Ref link Pubmed link
  • 123  Ji B, Jamet P, Perani EG, Bobin P, Grosset JH. Powerful bactericidal activities of clarithromycin and minocycline against Mycobacterium leprae in lepromatous leprosy. J Infect Dis 1993;168:18890. Cross Ref link Pubmed link
  • 124  Xiong JH, Ji B, Perani EG, Petinon C, Grosset JH. Further study of the effectiveness of single doses of clarithromycin and minocycline against Mycobacterium leprae in mice. Int J Lepr Other Mycobact Dis 1994;62:3742. Pubmed link
  • 125  Fleming CJ, Hunt MJ, Salisbury EL, et al. Minocycline‐induced hyperpigmentation in leprosy. Br J Dermatol 1996;134:7847. Cross Ref link Pubmed link
  • 126  Lockwood DN. Cunha G Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally. Lepr Rev 2012;83(3):2414. Pubmed link
  • 127  Rose P, Waters MF. Reversal reactions in leprosy and their management. Lepr Rev 1991;62:11321. Pubmed link
  • 128  Van Brakel WH. Peripheral neuropathy in leprosy and its consequences. Lepr Rev 2000;71(Suppl.):S14653. Pubmed link
  • 129  Croft RP, Richardus JH, Nicholls PG, Smith WC. Nerve function impairment in leprosy. Design, methodology, and intake status of a prospective cohort study of 2664 new leprosy cases in Bangladesh (the Bangladesh Acute Nerve Damage Study). Lepr Rev 1999;70:14059. Pubmed link
  • 130  Saunderson P, Gebre S, Desta K, et al. The pattern of leprosy‐related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev 2000;71:285308. Pubmed link
  • 131  Lienhardt C, Fine PE. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev 1994;65:933. Pubmed link
  • 132  Kiran KU, Stanley JN, Pearson JM. The outpatient treatment of nerve damage in patients with borderline leprosy using a semi‐standardized steroid regimen. Lepr Rev 1985;56:12734. Pubmed link
  • 133  Little D, Khanolkar‐Young S, Coulthart A, et al. Immunohistochemical analysis of cellular infiltrate and γ interferon, interleukin‐12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 2001;69:341317. Cross Ref link Pubmed link
  • 134  Walker SL, Nicholls PG, Dhakal S. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous Normal saline and oral prednisolone in individuals with leprosy Type 1 reactions and /or nerve function impairment. PLOS Negl Trop Dis 2011;Apr 12;5(4):e1041. Cross Ref link Pubmed link
  • 135  Marlowe SNS, Leekassa R, Bizuneh E, et al. Clinical response to cyclosporin A treatment in Ethiopian and Nepali patients with severe leprosy type 1 reactions (T1R). Trans R Soc Trop Med Hyg 2007;101:100412. Cross Ref link Pubmed link
  • 136  Walker SL, Waters M, Lockwood DNJ. The role of thalidomide in the management of erythema nodosum leprosum. Lep Rev 2007;78:197215.
  • 137  Watson JM. Preventing Disability in Leprosy Patients. London: the Leprosy Mission International, 1986.
  • 138  Srinivasan H. Prevention of Disabilities in Patients with Leprosy: a Practical Guide. Geneva: World Health Organization, 1986.
  • 139  Setia MS, Steinmaus C, Ho CS, Rutherford GW. The role of BCG in prevention of leprosy: a meta‐analysis. Lancet Infect Dis 2006;6:16270. Cross Ref link Pubmed link
  • 140  Ponnighaus JM, Fine PE, Sterne JA, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992;339:6369. Cross Ref link Pubmed link
  • 141  Convit J, Smith PG, Zuniga M, et al. BCG vaccination protects against leprosy in Venezuela: a case‐control study. Int J Lepr Other Mycobact Dis 1993;61:18591. Pubmed link
  • 142  Karonga Prevention Trial Group. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tberculosis in Malawi. Lancet 1996;348:1724. Cross Ref link Pubmed link
  • 143  Convit J, Sampson C, Zuniga M, et al. Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results. Lancet 1992;339:44650. Cross Ref link Pubmed link
  • 144  Anonymous. Bettering BCG. Lancet 1992;339:4623. Cross Ref link Pubmed link
  • 145  Lockwood DN, Shetty V, Penna GO. Hazards of targets to eliminate disease: lessons from the leprosy campaign. BMJ 2014;1521.